V600E

V600E is a mutation of the BRAF gene in which valine (V) is substituted by glutamic acid (E) at aminoacid 600. It is a driver mutation in a proportion of certain diagnoses, including melanoma,hairy cell leukemia,papillary thyroid carcinoma,colorectal cancer,non-small-cell lung cancer,Langerhans cell histiocytosis, and ameloblastoma.

Vemurafenib and dabrafenib are approved by the FDA for treatment of melanomas that express V600E.